Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2017 - 2026)

Kiniksa Pharmaceuticals International's Share-based Compensation history runs 10 years deep, the most recent figure standing at $93.0 million for Q1 2026.

• Quarterly Share-based Compensation rose 22476.21% year-over-year to $93.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.0 million (up 180.08% YoY) and the FY2025 annual result came in at $90.4 million, up 177.69% from the prior year.
• Share-based Compensation was $93.0 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from -$19.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $93.0 million in Q1 2026 and bottomed at -$19.0 million in Q4 2025.
• A 5-year average of $7.6 million and a median of $552000.0 in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 369.46% — and 2026, when it jumped 22476.21%.
• Kiniksa Pharmaceuticals International's Share-based Compensation stood at $6.4 million in 2022, then sank by 369.46% to -$17.2 million in 2023, then soared by 253.1% to $26.3 million in 2024, then plunged by 172.42% to -$19.0 million in 2025, then soared by 588.57% to $93.0 million in 2026.
• Business Quant data shows KNSA's Share-based Compensation at $93.0 million in Q1 2026, -$19.0 million in Q4 2025, and $11.9 million in Q3 2025.